CeMines takes lung cancer diagnostic:
This article was originally published in Clinica
CeMines has CE-marked for sale in Europe its molecular blood test kit for helping doctors diagnose lung cancer. The CellCorrect KvA-40 LAb kit, the first product from the firm's CellCorrect family of tests to reach the market, is accurate, simple-to-use and cost-effective, claims the Golden, Colorado-based company. It detects disease-related antibodies in the blood using CeMines' Molecular FingerPrinting bioinformatics technology, which evaluates cancer-related antibody patterns and their relevant statistical profiles; the test is able to differentiate and characterise the cancer. Its data are presented in an easy-to-read "score format" that does not require subjective interpretation by physicians. In the US, CeMines filed a 510(k) marketing application for the test in May last year.